LogicBio Therapeutics, Inc. Common Stock
LOGC
LOGC was delisted on the 15th of November, 2022.
47 hedge funds and large institutions have $917K invested in LogicBio Therapeutics, Inc. Common Stock in 2022 Q2 according to their latest regulatory filings, with 7 funds opening new positions, 6 increasing their positions, 12 reducing their positions, and 6 closing their positions.
17% more first-time investments, than exits
New positions opened: 7 | Existing positions closed: 6
2% more funds holding
Funds holding: 46 → 47 (+1)
50% less repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 12
89% less capital invested
Capital invested by funds: $8.66M → $917K (-$7.75M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Prudential Financial
Newark,
New Jersey
|
+$32.4K |
| 2 |
Jane Street
New York
|
+$26K |
| 3 |
IBOK
Independence Bank of Kentucky
Owensboro,
Kentucky
|
+$16.2K |
| 4 |
UBS Group
Zurich,
Switzerland
|
+$10.8K |
| 5 |
TRCT
Tower Research Capital (TRC)
New York
|
+$4.82K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Franklin Resources
San Mateo,
California
|
-$310K |
| 2 |
Goldman Sachs
New York
|
-$251K |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
-$159K |
| 4 |
SCM
Sio Capital Management
New York
|
-$124K |
| 5 |
VF
Virtu Financial
New York
|
-$49K |
LOGC Hedge Fund Activity: Q2 2022 in Review
47 of the 5,936 institutional investors tracked by Wall St. Rank reported a position in LogicBio Therapeutics, Inc. Common Stock (LOGC) for Q2 2022, worth a combined $917K — down 89% from $8.66M a quarter earlier.
Buyers outnumbered sellers: 7 funds opened new LOGC positions and 6 closed out — a net gain of 1 holder — while 6 added to existing stakes and 12 trimmed.
The largest buyer was Prudential Financial, opening a new position worth an estimated $32.4K. The largest seller was Franklin Resources, cutting an estimated $310K.
- 47 institutional investors held LogicBio Therapeutics, Inc. Common Stock (LOGC) as of Q2 2022, up from 46 in Q1 2022.
- Funds reported $917K of LogicBio Therapeutics, Inc. Common Stock stock for Q2 2022, down 89% quarter-over-quarter.
- 7 funds opened new LogicBio Therapeutics, Inc. Common Stock positions in Q2 2022 and 6 closed out, a net change of +1 holder.
- The largest LogicBio Therapeutics, Inc. Common Stock buyer in Q2 2022 was Prudential Financial, an estimated $32.4K added.
- The largest LogicBio Therapeutics, Inc. Common Stock seller in Q2 2022 was Franklin Resources, an estimated $310K sold.
Based on aggregated 13F filings for Q2 2022.